PortalPublikationenPax-5 immunoexpression in various types of benign and malign...

Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.

Standard

Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. / Mhawech-Fauceglia, Paulette; Saxena, Rhakee; Zhang, Shaozeng; Terracciano, Luigi; Sauter, Guido; Chadhuri, Arundhuti; Herrmann, Francois R; Penetrante, Remedios.

in: J CLIN PATHOL, Jahrgang 60, Nr. 6, 6, 2007, S. 709-714.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Mhawech-Fauceglia, P, Saxena, R, Zhang, S, Terracciano, L, Sauter, G, Chadhuri, A, Herrmann, FR & Penetrante, R 2007, 'Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.', J CLIN PATHOL, Jg. 60, Nr. 6, 6, S. 709-714. <http://www.ncbi.nlm.nih.gov/pubmed/16837628?dopt=Citation>

APA

Mhawech-Fauceglia, P., Saxena, R., Zhang, S., Terracciano, L., Sauter, G., Chadhuri, A., Herrmann, F. R., & Penetrante, R. (2007). Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J CLIN PATHOL, 60(6), 709-714. [6]. http://www.ncbi.nlm.nih.gov/pubmed/16837628?dopt=Citation

Vancouver

Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A et al. Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J CLIN PATHOL. 2007;60(6):709-714. 6.

Bibtex

@article{e6871a450a1449918e3a29fe54b0bea7,
title = "Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.",
abstract = "BACKGROUND: Pax-5 belongs to the Pax gene family transcription factors that play an important role in organogenesis and in B cell ontogeny. It is expressed in B cell non-Hodgkin's lymphoma (B-NHL), Hodgkin's lymphoma (HL) and neuroendocrine carcinomas. However, its expression in other tumour types is not fully explored. Aims and methods: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections. RESULTS: Pax-5 was expressed in 108/118 (91.5%) B-NHLs, in 60/70 (85.7%) HLs and in 0/7 T cell lymphomas. In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder. CONCLUSION: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.",
author = "Paulette Mhawech-Fauceglia and Rhakee Saxena and Shaozeng Zhang and Luigi Terracciano and Guido Sauter and Arundhuti Chadhuri and Herrmann, {Francois R} and Remedios Penetrante",
year = "2007",
language = "Deutsch",
volume = "60",
pages = "709--714",
journal = "J CLIN PATHOL",
issn = "0021-9746",
publisher = "BMJ PUBLISHING GROUP",
number = "6",

}

RIS

TY - JOUR

T1 - Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.

AU - Mhawech-Fauceglia, Paulette

AU - Saxena, Rhakee

AU - Zhang, Shaozeng

AU - Terracciano, Luigi

AU - Sauter, Guido

AU - Chadhuri, Arundhuti

AU - Herrmann, Francois R

AU - Penetrante, Remedios

PY - 2007

Y1 - 2007

N2 - BACKGROUND: Pax-5 belongs to the Pax gene family transcription factors that play an important role in organogenesis and in B cell ontogeny. It is expressed in B cell non-Hodgkin's lymphoma (B-NHL), Hodgkin's lymphoma (HL) and neuroendocrine carcinomas. However, its expression in other tumour types is not fully explored. Aims and methods: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections. RESULTS: Pax-5 was expressed in 108/118 (91.5%) B-NHLs, in 60/70 (85.7%) HLs and in 0/7 T cell lymphomas. In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder. CONCLUSION: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.

AB - BACKGROUND: Pax-5 belongs to the Pax gene family transcription factors that play an important role in organogenesis and in B cell ontogeny. It is expressed in B cell non-Hodgkin's lymphoma (B-NHL), Hodgkin's lymphoma (HL) and neuroendocrine carcinomas. However, its expression in other tumour types is not fully explored. Aims and methods: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections. RESULTS: Pax-5 was expressed in 108/118 (91.5%) B-NHLs, in 60/70 (85.7%) HLs and in 0/7 T cell lymphomas. In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder. CONCLUSION: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.

M3 - SCORING: Zeitschriftenaufsatz

VL - 60

SP - 709

EP - 714

JO - J CLIN PATHOL

JF - J CLIN PATHOL

SN - 0021-9746

IS - 6

M1 - 6

ER -